Mazdutide vs NAD+ — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Mazdutide (IBI362) is a once-weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics. By activating both receptors simultaneously, it combines the appetite suppression and insulin-sensitizing effects of GLP-1 agonism with the fat-oxidizing and energy-expenditu...
Calculate Mazdutide dose →NAD+ is a coenzyme present in every cell, essential for mitochondrial ATP production via electron transport, DNA repair via PARP enzymes, and sirtuin deacetylase activation. Levels decline approximately 50% between age 20 and 60. Restored through IV therapy or oral precursors NMN...
Calculate NAD+ dose →| Parameter | Mazdutide | NAD+ |
|---|---|---|
| Category | Metabolic & Mitochondrial | Metabolic & Mitochondrial |
| Research | Phase III (China) | Widely Studied |
| Half-Life | ~7 days | Very short (direct IV); precursors have hours-long kinetics |
| Typical Dose | 3–9 mg | 250–1,000 mg (IV) |
| Frequency | Once weekly | 2–3x weekly (IV therapy); daily (oral precursors) |
| Route | Subcutaneous (weekly) | IV / IM / Oral (as precursors NMN, NR) |
| FDA Status | Not Approved | Not Approved (drug use) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.